-
2023-507372-42-00
4
2021-09-20
Schizophrenia
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-509254-58-00
7
2021-05-31
Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Ly
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-514010-12-00
1
2020-12-03
Advanced Malignancies
-
2024-511454-45-00
7
2020-11-09
Relapsed or Refractory Multiple Myeloma
-
2024-513100-34-00
1
2020-07-15
Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressin
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2023-507794-17-00
4
2019-11-11
Childhood Epilepsy
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2025-521519-37-00
4
2025-10-10
IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2025-520488-42-00
4
2025-09-17
Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-516745-39-00
4
2025-07-11
Cutaneous lupus erythematosus